Increasing the dose of imatinib (IM) is well tolerated and leads to clinical improvement in a significant number of patients (pts) with chronic myeloid leukemia (CML) - first data of the observational DOSING study

O. Frank,L-O Muegge, C. Scheid, E. Schaefer, A. Lueck, C. Scheidegger, A. Distelrath, D. Plewe, G. Gauch, P. Bruhn, S. Korsten,O. Maywald, U. Sauer, U. Soeling, F. Heits, K. Blymenstengel, V Lakner, C. Lerchenmueller, U. Ritter, A. Hochhaus

ONKOLOGIE（2010）

引用 0|浏览2